Abstract
The aim of this study was to test the hypothesis that inhibiting mammalian target of rapamycin and insulin-like growth factor-1 receptor would be efficacious in metastatic uveal melanoma. This was a phase 2 trial of everolimus 10 mg daily plus pasireotide long-acting release 60 mg every 28 days enrolling patients with progressive, metastatic uveal melanoma to treatment until progression by Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1) or unacceptable toxicity. The primary endpoint was clinical benefit rate, defined as any objective response or RECIST 1.1 stable disease at 16 weeks. A subset of patients underwent baseline indium-111-octreotide scans. A total of 14 patients were enrolled, of which 13 were evaluable for the primary endpoint, before the study was terminated due to poor accrual. Three of 13 (26%) patients obtained clinical benefit. Seven of 13 (54%) had stable disease lasting for a median of 8 weeks (range: 8-16 weeks). Grade 3 adverse events deemed at least possibly related to study drugs were hyperglycemia (n=7), oral mucositis (n=2), diarrhea (n=1), hypophosphatemia (n=1), and anemia (n=1). Seven of 14 (50%) patients required at least one dose reduction due to toxicity. Seven of eight (88%) patien...Continue Reading
References
Feb 26, 2003·Investigative Ophthalmology & Visual Science·Navid ArdjomandYosuf El-Shabrawi
Oct 28, 2003·Investigative Ophthalmology & Visual Science·Emma KujalaTero Kivelä
May 4, 2004·Nature Reviews. Cancer·Mary-Ann Bjornsti, Peter J Houghton
Nov 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Petra RietschelPaul B Chapman
Dec 14, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mohamed H Abdel-RahmanCharis Eng
Feb 3, 2006·Cancer Research·Kathryn E O'ReillyNeal Rosen
Feb 21, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ada GirnitaLeonard Girnita
Dec 17, 2008·Nature·Catherine D Van RaamsdonkBoris C Bastian
Feb 25, 2010·Annals of Surgical Oncology·Stephen B Edge, Carolyn C Compton
Nov 19, 2010·The New England Journal of Medicine·Catherine D Van RaamsdonkBoris C Bastian
Jun 28, 2011·Ophthalmology·Arun D SinghAllan K Topham
Feb 22, 2012·Journal of Medical Imaging and Radiation Oncology·Michael S HofmanRodney J Hicks
Jun 27, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jahan S KhaliliScott E Woodman
Nov 21, 2012·Melanoma Research·Matias E ValsecchiTakami Sato
Oct 22, 2013·Oncogene·X ChenB C Bastian
Apr 30, 2014·Oncology·Linda CerbonePatrick Schöffski
Jun 6, 2014·Molecular Cancer Therapeutics·Grazia AmbrosiniGary K Schwartz
Jun 19, 2014·JAMA : the Journal of the American Medical Association·Richard D CarvajalGary K Schwartz
Oct 12, 2014·Melanoma Research·Alexander N Shoushtari, Richard D Carvajal
Citations
Mar 24, 2016·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Francesco SpagnoloPaola Queirolo
May 9, 2018·Pigment Cell & Melanoma Research·John J ParkHelen Rizos
Jun 21, 2019·Cancers·Michela CroceRosaria Gangemi
Aug 5, 2020·Acta Ophthalmologica·Lauge Hjorth Mikkelsen
Sep 12, 2020·Cancers·Cristina Rodriguez-VidalManuel Bande
Oct 1, 2020·Cancers·Fabiana MalloneAntonietta Moramarco
Nov 6, 2020·Therapeutic Advances in Medical Oncology·Yongyun LiXianqun Fan
Apr 11, 2021·The FEBS Journal·Janney Z WangWenying Shu
Aug 26, 2021·Future Oncology·Francesca ComitoBarbara Melotti